Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Paroxysmal Atrial Fibrillation Burden Reduction
ChiCTR2200058691Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Burden of atrial fibrillation. Planned start May 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2200058691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058691.